Max Kurlbaum

Comparison of a newly developed high performance liquid chromatography method with diode array detection to a liquid chromatography tandem mass spectrometry method for the quantification of cabozantinib, dabrafenib, nilotinib and osimertinib in human serum - Application to therapeutic drug monitorin

A. Gesierich, C. Kalogirou, O. Scherf-Clavel, 2022, Clinical biochemistry.

Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma

A. Gesierich, O. Scherf-Clavel, H. Klinker, 2022, Cancers.

Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice—a prospective single-center trial

O. Scherf-Clavel, H. Klinker, S. Kraus, 2021, Cancer Chemotherapy and Pharmacology.

Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma

O. Scherf-Clavel, H. Klinker, M. Kurlbaum, 2020, Analytical and Bioanalytical Chemistry.

A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug–Drug Interaction Frequently Observed in Graft versus Host Disease Patients

Bettina Gerner, O. Scherf-Clavel, H. Klinker, 2022, Pharmaceutics.